Navigation Links
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia
Date:11/18/2011

LANGHORNE, Pa. and OXFORD, England, Nov. 18, 2011 /PRNewswire/ --  EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that the US Food and Drug Administration (FDA) has approved its orphan drug ERWINAZE™ (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to E. coli-derived asparaginase.  ERWINAZE will be available to patients throughout the United States immediately.

ALL is the most common form of childhood cancer, with approximately 2,900 patients under the age of 20 diagnosed in the USA each year [1].  It is also one of the most curable forms of cancer, with remission rates in treated children of over 95% and 75 – 85% surviving at least five years without recurrence of leukemia [1].  Treatment involves a number of stages and drugs, and typically includes asparaginase as an essential component of current protocols.  ERWINAZE is indicated as an integral part of a multi-agent regimen for the treatment of ALL patients who develop hypersensitivity to current products derived from E. coli, and is therefore the first and only approved treatment option available for patients with hypersensitivity to standard-of-care treatment with pegaspargase.  An estimated 15 - 20% of ALL patients develop hypersensitivity to E. coli-derived asparaginase, representing approximately 450 - 600 children in the United States each year [2]. 

"Treatment with asparaginase is a vital and life-saving therapy for thousands of patients, mostly children, with acute lymphoblastic leukemia each year.  Unfortunately, a number of these patients develop hypersensitivity to asparaginases derived from E. coli, including pegaspargase, and are unable to complete the recommended course of treatment.  The approval of ERWINAZE is
'/>"/>

SOURCE EUSA Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Par Pharmaceutical Completes Acquisition of Anchen
2. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
3. Genesis Biopharmas Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI
4. Assured Pharmacy Reports Financial Results for the Third Quarter of 2011
5. PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference
6. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
7. Idenix Pharmaceuticals Prices Public Offering of Common Stock
8. Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
9. Pharmaceutical Investment & Cost Benchmarks Accessed Quickly Through Best Practices, LLCs New Database Search Function
10. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
11. Radient Pharmaceuticals Asks DHS Holding Co. to Retract News Release Saying It Will Enter Into Talks With Radient Pharmaceuticals Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... 29, 2011 UBM Canon,s leading brand, Japan Medical Design ... the launch of its new Japanese-language website with enhanced content and ... website allows users to find the resources and information they ... Editor-in-Chief, EMDT , JMDMT , and CMDM ...
... June 29, 2011 Cayenne Medical, Inc., a private ... II Meniscal Repair System, its second generation device for ... on display at the 2011 American Orthopaedic Society for ... CA.   Tal David, MD, orthopedic sports ...
Cached Medicine Technology:UBM Canon Announces New Japanese-Language Website for Japan Medical Design & Manufacturing Technology: www.jmdmt.com 2Cayenne Medical, Inc. Launches CrossFix® II Meniscal Repair System 2
(Date:8/28/2015)... ... 28, 2015 , ... Approximately 2,000 United Methodists are expected ... helping children, a thank you to the many creative and generous ways in ... United Methodist initiative to end malaria deaths. , The Columbus Zoo and Aquarium ...
(Date:8/28/2015)... ... 2015 , ... An article published August 19th by the LA ... through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior ... but the current process, having already gone on for over a year, is taking ...
(Date:8/28/2015)... TX (PRWEB) , ... August 28, 2015 , ... For ... Center is taking part with their subsidiary USPI Tenet Health. , The American Heart ... fight heart disease and stroke. They believe that together, a difference can be made. ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily ... FDA clearance for results that last for two years, the longest of any cellulite ... who are looking for a long-lasting, effective solution for their cellulite, according to Dr. ...
(Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... On ... Western Michigan, joined as sponsor of the “Music With A Mission” benefit concert in ... behind the event was to raise money to support music education programs in the ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... the second year in a row, the American Red Cross and ... their families around the world this holiday season. This year a ... 300 military installations and hospitals around the world. , ... , There are many ways you can ...
... 2007, - ... - Debt financing is ... VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ - CRH Medical Corporation (CRM:TSX-V) announced today ... and unveiled a new strategy designed to mitigate the need to obtain ...
... Streamline Health Solutions, Inc. (Nasdaq: STRM ) ... E. Vick, Jr., as the Company,s interim Chief Financial Officer ... Officer. Mr. Vick may be considered as a candidate ... Chief Financial Officer, Mr. Vick will also continue to serve ...
... Watson Pharmaceuticals,Inc. (NYSE: WPI ... announced,that its subsidiary, Watson Laboratories, Inc., has ... Food and Drug Administration on its Abbreviated,New ... (XL) in the 150 mg strength. ...
... may be affected by phthalates in these products, experts ... exposed to a common hairspray chemical while at work ... an abnormally placed urinary opening, a new report says. ... nail and hair products contain chemicals called phthalates, such ...
... WASHINGTON, Nov. 26 Talk about being a Grinch! On ... of the government workforce -- are having their benefits cut ... , That,s right, BCBS has drastically altered a ... upon for their healthcare coverage -- and hasn,t bothered to ...
Cached Medicine News:Health News:Remember to Send 'Holiday Mail For Heroes' and Thank a Service Member this Thanksgiving 2Health News:CRH Medical reports Q3 2008 results 2Health News:CRH Medical reports Q3 2008 results 3Health News:CRH Medical reports Q3 2008 results 4Health News:CRH Medical reports Q3 2008 results 5Health News:CRH Medical reports Q3 2008 results 6Health News:Streamline Health Announces Appointment of Interim Chief Financial Officer 2Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg 2Health News:Blue Cross/Blue Shield Christmas Gift to Federal Employees: Surprise, We're Cutting Your Benefits!; Patients, Doctors and Health Care Providers Outraged 2
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
... management of diabetes in order to maintain tight ... effective way to reduce or even prevent diabetes-related ... improving a diabetes patients quality of life, however, ... have been the guiding factors in the development ...
... by the CGMS System Gold can assist ... program based on detailed glycemic profiles. Its ... improve motivation and collaboration with patients.1, ... with all diabetes patients, it may be ...
... Biographer is intended for detecting trends and ... (aged 18 and older) and children/adolescents (aged ... supervise the use of the G2 Biographer ... intended to supplement, not replace, conventional blood ...
Medicine Products: